Literature DB >> 29312485

Combined preconditioning with hypoxia and GYKI-52466 protects rats from cerebral ischemic injury by HIF-1α/eNOS pathway.

Yuchan Yang1, Fang Lu1, Lihua Zhuang1, Shuohui Yang1, Yingnan Kong1, Wenli Tan1, Zhigang Gong1, Songhua Zhan1.   

Abstract

Cerebral ischemic injury has been the leading cause of death and long term disability in the world because of the lack of successful therapies to it, leading to neurological and behavioral deficits. The present study aims to investigate the effects of combined preconditioning (PC) with hypoxia and GYKI-52466 (GYKI) on cerebral ischemic injury and to explore the mechanism. The results showed that combined preconditioning with hypoxia and GYKI-52466 increased the survival rate of cerebral ischemia rats, alleviated the neurological deficit, increased the object recognition and social recognition memory of rats and suppressed the inflammatory reaction induced by cerebral ischemia. Further experiments found that preconditioning with hypoxia and GYKI-52466 significantly increased the HIF-1α and eNOS expression as well as eNOS activity, while inhibitors of HIF-1α and eNOS abolished the protective effects of hypoxia+GYKI PC on neurological deficit. Taken together, these results indicate that combined preconditioning with hypoxia and GYKI-52466 is effective to prevent cerebral ischemia injury, while HIF-1α and eNOS may be involved in the mechanism.

Entities:  

Keywords:  Cerebral ischemic injury; GYKI-52466; HIF-1α; eNOS; hypoxia; preconditioning

Year:  2017        PMID: 29312485      PMCID: PMC5752883     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  35 in total

1.  GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses.

Authors:  S D Donevan; M A Rogawski
Journal:  Neuron       Date:  1993-01       Impact factor: 17.173

Review 2.  Molecular mechanisms of cerebral ischemia-induced neuronal death.

Authors:  Sheng T Hou; John P MacManus
Journal:  Int Rev Cytol       Date:  2002

3.  Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures.

Authors:  V L Dawson; T M Dawson; D A Bartley; G R Uhl; S H Snyder
Journal:  J Neurosci       Date:  1993-06       Impact factor: 6.167

4.  Pretreatment but not posttreatment with GYKI 52466 reduces functional deficits and neuronal damage after global ischemia in rats.

Authors:  F Block; W Schmitt; M Schwarz
Journal:  J Neurol Sci       Date:  1996-08       Impact factor: 3.181

5.  Atorvastatin attenuates cognitive deficits through Akt1/caspase-3 signaling pathway in ischemic stroke.

Authors:  Jie Yang; Ying Pan; Xuejing Li; Xianying Wang
Journal:  Brain Res       Date:  2015-10-24       Impact factor: 3.252

6.  Comparative anticonvulsant activity of some 2,3-benzodiazepine derivatives in rodents.

Authors:  Giovambattista De Sarro; Guido Ferreri; Pietro Gareri; Emilio Russo; Angela De Sarro; Rosaria Gitto; Alba Chimirri
Journal:  Pharmacol Biochem Behav       Date:  2003-02       Impact factor: 3.533

7.  GYKI 52466 [1-(4-aminophenyl)-4-methoxy-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride] and the anticonvulsive activity of conventional antiepileptics against pentetrazol in mice.

Authors:  S J Czuczwar; M Gasior; R Kamiński; Z Kleinrok; M Kozicka; G Ossowska; T Pietrasiewicz
Journal:  Mol Chem Neuropathol       Date:  1998-04

8.  Centella asiatica attenuates the neurobehavioral, neurochemical and histological changes in transient focal middle cerebral artery occlusion rats.

Authors:  Rizwana Tabassum; Kumar Vaibhav; Pallavi Shrivastava; Andleeb Khan; Md Ejaz Ahmed; Hayate Javed; Farah Islam; Sayeed Ahmad; M Saeed Siddiqui; Mohammed M Safhi; Fakhrul Islam
Journal:  Neurol Sci       Date:  2012-08-04       Impact factor: 3.307

9.  Neuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal models.

Authors:  G Gigler; K Móricz; M Agoston; A Simó; M Albert; A Benedek; G Kapus; S Kertész; M Vegh; J Barkóczy; B Markó; G Szabó; E Matucz; I Gacsályi; G Lévay; L G Hársing; G Szénási
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

10.  Acute migraine therapy: new drugs and new approaches.

Authors:  Teshamae S Monteith; Peter J Goadsby
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

View more
  4 in total

1.  Combined Preconditioning Reduces the Negative Influence of Cerebral Ischemia on the Morphofunctional Condition of CNS.

Authors:  O S Levchenkova; V E Novikov; Yu S Korneva; A E Dorosevich; E A Parfenov
Journal:  Bull Exp Biol Med       Date:  2021-09-20       Impact factor: 0.804

Review 2.  HIF‑1α in cerebral ischemia (Review).

Authors:  Peiliang Dong; Qingna Li; Hua Han
Journal:  Mol Med Rep       Date:  2021-12-08       Impact factor: 2.952

3.  Neuroprotective potential of imatinib in global ischemia-reperfusion-induced cerebral injury: possible role of Janus-activated kinase 2/signal transducer and activator of transcription 3 and connexin 43.

Authors:  Jieying Wang; Taomin Bai; Nana Wang; Hongyan Li; Xiangyang Guo
Journal:  Korean J Physiol Pharmacol       Date:  2020-12-20       Impact factor: 2.016

4.  Role of the glutamatergic system of ventrolateral periaqueductal gray (vlPAG) in the cardiovascular responses in normal and hemorrhagic conditions in rats.

Authors:  Vida Alikhani; Reza Mohebbati; Mahmoud Hosseini; Abolfazl Khajavirad; Mohammad Naser Shafei
Journal:  Iran J Basic Med Sci       Date:  2021-05       Impact factor: 2.699

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.